TVM Capital
VC Fund
Munich, Germany
TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.
- Total investments:
- 103
- Last investment:
- Lead investor:
- 18%
- Fund size:
- $290M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries TVM Capital invests in
BiotechnologyHealth CarePharmaceuticalSoftwareMedical
Stages TVM Capital invests in
Series BSeries CFunding RoundSeries ASeries D
Countries TVM Capital invests in
United StatesGermanyUnited KingdomItalyThe Netherlands
Round sizes
Series B $7.5M–$50MSeries C $10M–$55M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series B
- $7.5M–$50M
- Series C
- $10M–$55M
Investment Focus
Industry
- Biotechnology 30 (29%)
- Health Care 18 (17%)
- Pharmaceutical 13 (13%)
- Software 11 (11%)
- Medical 9 (9%)
Stage
- Series B 25 (24%)
- Series C 18 (17%)
- Funding Round 18 (17%)
- Series A 15 (15%)
- Series D 10 (10%)
Country
- United States 27 (26%)
- Germany 14 (14%)
- United Kingdom 4 (4%)
- Italy 2 (2%)
- The Netherlands 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hubert Birner
General Partner
|
General Partner | Total investments: 8 | Find email | |
Luc Marengere
Managing Partner
|
Managing Partner | Total investments: 11 | Find email | |
|
Christoph Schröder
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Friedrich Bornikoel
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Marc Riviere
General Partner
|
General Partner | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Lamab Biologics
|
Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases. | $25M / Venture - Series Unknown / Feb 08, 2023 | |
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $25M / Series C / Apr 29, 2015 | ||
| Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. | $20.4M / Venture - Series Unknown / Jun 23, 2014 | ||
| Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M / Series D / May 16, 2014 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $6M / Venture - Series Unknown / Apr 04, 2014 | ||
| invendo medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology.Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendomedical´s goal is to improve patient compliance and thereby increase the number of procedures performed. | $28M / Venture - Series Unknown / Mar 20, 2014 | ||
| Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.5M / Series E / Nov 20, 2013 | ||
| F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecificantibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK. | $9.4M / Series A / Oct 23, 2013 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $32.6M / Series B / Jun 26, 2013 | ||
| Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. | $10.6M / Oct 01, 2012 | ||
| See all 103 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
SaaS Investors
118,083 investors
Software Investors
57,577 investors
Health Care Investors
48,825 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
Medical Investors
21,329 investors
SaaS VC Funds
72,248 investors
Software VC Funds
36,729 investors
Health Care VC Funds
36,610 investors
FAQ
What does TVM Capital invest in?
TVM Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 103 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does TVM Capital invest in?
TVM Capital typically joins rounds of $7.5M–$50M at Series B and $10M–$55M at Series C. These are whole funding-round sizes, not TVM Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds TVM Capital took part in.
How do I contact TVM Capital?
Public channels for TVM Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TVM Capital?
The team at TVM Capital includes Hubert Birner (General Partner), Luc Marengere (Managing Partner) and Christoph Schröder (General Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
